- Home
- KRRO vs EDIT Comparison
KRRO vs EDIT Comparison
Compare KRRO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- EDIT
- Stock Information
- Founded
- KRRO 2014
- EDIT 2013
- Country
- KRRO United States
- EDIT United States
- Employees
- KRRO N/A
- EDIT N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRRO Health Care
- EDIT Health Care
- Exchange
- KRRO Nasdaq
- EDIT Nasdaq
- Market Cap
- KRRO 320.9M
- EDIT 327.0M
- IPO Year
- KRRO 2019
- EDIT 2016
- Fundamental
- Price
- KRRO $33.59
- EDIT $3.38
- Analyst Decision
- KRRO Strong Buy
- EDIT Buy
- Analyst Count
- KRRO 5
- EDIT 11
- Target Price
- KRRO $123.75
- EDIT $10.50
- AVG Volume (30 Days)
- KRRO 65.7K
- EDIT 2.1M
- Earning Date
- KRRO 11-27-2024
- EDIT 11-01-2024
- Dividend Yield
- KRRO N/A
- EDIT N/A
- EPS Growth
- KRRO N/A
- EDIT N/A
- EPS
- KRRO N/A
- EDIT N/A
- Revenue
- KRRO N/A
- EDIT $67,034,000.00
- Revenue This Year
- KRRO N/A
- EDIT N/A
- Revenue Next Year
- KRRO N/A
- EDIT N/A
- P/E Ratio
- KRRO N/A
- EDIT N/A
- Revenue Growth
- KRRO N/A
- EDIT 247.04
- 52 Week Low
- KRRO $9.15
- EDIT $3.15
- 52 Week High
- KRRO $97.91
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- KRRO 39.03
- EDIT 39.94
- Support Level
- KRRO $31.62
- EDIT $3.15
- Resistance Level
- KRRO $36.69
- EDIT $3.63
- Average True Range (ATR)
- KRRO 2.75
- EDIT 0.19
- MACD
- KRRO -0.26
- EDIT -0.01
- Stochastic Oscillator
- KRRO 23.71
- EDIT 23.71
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.